Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Forecast EPS for 2021

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Dec 07, 2021 11:55am

130 Views

Post# 34206589

RE:Forecast EPS for 2021

At the current SP, the price/earnings ratio is just over 8.
It makes no sense to exclude impairment charges.
Due to the nature of their business, there have been several impairment charges in past years & they will likely continue .. which is the reason I sold a while back.

If the SP drops further, I may get back in.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle